NAB-Paclitaxel Plus Carboplatin As First-Line Therapy for Patients with Advanced NSCLC in the Real-World Setting: Safety Results of the Non-Interventional Neptun Study

被引：0
|
作者：
Dechow, Tobias [1 ]
Riera-Knorrenschild, Jorge [2 ]
Hackanson, Bjoern [3 ]
von Weikersthal, Ludwig Fischer [4 ]
Chiabudini, Marco [5 ]
Timm, Barbara [5 ]
Zerbes, Ralf Michael [5 ]
Potthoff, Karin [5 ]
机构：
[1] Onkol Hamatol Ravensburg, Ravensburg, Germany
[2] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany
[3] Univ Klinikum Augsburg, Augsburg, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Georgia
[5] IOMEDICO AG, Freiburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
276
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO
    Marschner, N.
    Potthoff, K.
    Salat, C.
    Soeling, U.
    Hansen, R.
    Grebhardt, S.
    Horde, J.
    Nusch, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 183 - 183
  • [22] S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
    Shi, Yan
    Han, Quanli
    Yan, Huan
    Lv, Yao
    Yuan, Jing
    Li, Jie
    Guan, Shasha
    Wang, Zhikuan
    Huang, Lei
    Dai, Guanghai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
    Gridelli, C.
    Li, L.
    O'Brien, M.
    Ong, T. J.
    Pirker, R.
    Socinski, M. A.
    Thomas, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S638 - S639
  • [24] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [25] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [26] Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC).
    Hawkins, M. J.
    Georgy, M.
    Makhson, A.
    Cheporov, S.
    Sergey, O.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
  • [27] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [28] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [29] Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
    Socinski, M. A.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Dakhil, S. R.
    Page, R. D.
    Orsini, J.
    Yamamoto, N.
    Zhang, H.
    Renschler, M. F.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2390 - 2396
  • [30] Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes
    Hirsh, Vera
    Ko, Amy
    Pilot, Richard
    Renschler, Markus F.
    Socinski, Mark A.
    CLINICAL LUNG CANCER, 2016, 17 (05) : 367 - 374
12345